MAPK14 and craniosynostosis: Our evidence supports p38α MAPK as a potential therapeutic target for craniosynostosis, as pharmacological or genetic attenuation of p38α MAPK and conditional knockout (cKO) of Mapk14 effectively prevents SPC senescence, mitigates suture fusion and craniofacial deformities in Crouzon mice.